These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 33706221)

  • 1. Predictors of reoccurrence of congestive signs within 180 days after successful treatment of the first episode of congestive heart failure in dogs with myxomatous mitral valve disease.
    Franchini A; Abbott JA; Tyrrell W; Rosenthal S; Lahmers S; Menciotti G; Crosara S; Häggström J; Borgarelli M
    J Vet Cardiol; 2021 Apr; 34():112-119. PubMed ID: 33706221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prevalence of pulmonary hypertension in Cavalier King Charles spaniels compared with other breeds with myxomatous mitral valve disease.
    Sudunagunta S; Green D; Christley R; Dukes-McEwan J
    J Vet Cardiol; 2019 Jun; 23():21-31. PubMed ID: 31174726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Echocardiographic parameters for the assessment of congestive heart failure in dogs with myxomatous mitral valve disease and moderate to severe mitral regurgitation.
    Morgan KRS; Monteith G; Raheb S; Colpitts M; Fonfara S
    Vet J; 2020 Sep; 263():105518. PubMed ID: 32928487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Left atrial deformation and phasic function determined by two-dimensional speckle-tracking echocardiography in dogs with myxomatous mitral valve disease.
    Caivano D; Rishniw M; Birettoni F; Patata V; Giorgi ME; Porciello F
    J Vet Cardiol; 2018 Apr; 20(2):102-114. PubMed ID: 29459124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Left Atrial Strain at Different Stages of Myxomatous Mitral Valve Disease in Dogs.
    Nakamura K; Kawamoto S; Osuga T; Morita T; Sasaki N; Morishita K; Ohta H; Takiguchi M
    J Vet Intern Med; 2017 Mar; 31(2):316-325. PubMed ID: 28145607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Longitudinal Outcome Of Canine (K9) myxomatous mitral valve disease (LOOK-Mitral registry): Baseline characteristics.
    Franchini A; Borgarelli M; Abbott JA; Menciotti G; Crosara S; Häggström J; Lahmers S; Rosenthal S; Tyrrell W
    J Vet Cardiol; 2021 Aug; 36():32-47. PubMed ID: 34062479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incremental predictive value of echocardiographic indices of right ventricular function in the assessment of long-term prognosis in dogs with myxomatous mitral valve disease.
    Morita T; Nakamura K; Osuga T; Takiguchi M
    J Vet Cardiol; 2022 Feb; 39():51-62. PubMed ID: 34979482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral blood lymphocyte subtypes in dogs with different stages of myxomatous mitral valve disease.
    Druzhaeva N; Nemec Svete A; Ihan A; Pohar K; Domanjko Petrič A
    J Vet Intern Med; 2021 Sep; 35(5):2112-2122. PubMed ID: 34236111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study.
    Häggström J; Boswood A; O'Grady M; Jöns O; Smith S; Swift S; Borgarelli M; Gavaghan B; Kresken JG; Patteson M; Åblad B; Bussadori CM; Glaus T; Kovačević A; Rapp M; Santilli RA; Tidholm A; Eriksson A; Belanger MC; Deinert M; Little CJ; Kvart C; French A; Rønn-Landbo M; Wess G; Eggertsdottir A; Lynne O'Sullivan M; Schneider M; Lombard CW; Dukes-McEwan J; Willis R; Louvet A; DiFruscia R
    J Vet Intern Med; 2013; 27(6):1441-51. PubMed ID: 24010489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure.
    Häggström J; Lord PF; Höglund K; Ljungvall I; Jöns O; Kvart C; Hansson K
    J Vet Intern Med; 2013; 27(6):1452-62. PubMed ID: 24128373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of a mitral regurgitation severity index to predict long-term outcome in dogs with myxomatous mitral valve disease.
    Vereb M; Atkins CE; Adin D; Blondel T; Coffman M; Lee S; Guillot E; Ward JL
    J Vet Intern Med; 2024; 38(1):51-60. PubMed ID: 37909399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of left atrial stiffness estimated using echocardiography in dogs with myxomatous mitral valve disease.
    Osuga T; Kuroda K; Morita T; Sasaki N; Nakamura K; Takiguchi M
    J Vet Cardiol; 2023 Feb; 45():15-26. PubMed ID: 36608614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased serum C-reactive protein concentrations in dogs with congestive heart failure due to myxomatous mitral valve disease.
    Reimann MJ; Ljungvall I; Hillström A; Møller JE; Hagman R; Falk T; Höglund K; Häggström J; Olsen LH
    Vet J; 2016 Mar; 209():113-8. PubMed ID: 26831162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Echocardiographic evaluation of deformity and enlargement of the canine mitral valve annulus associated with myxomatous degenerative mitral valve disease.
    Mihara K; Kanemoto I; Sato K; Yasuhira Y; Watanabe I; Misumi K
    J Vet Cardiol; 2021 Oct; 37():8-17. PubMed ID: 34507141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dietary intervention reduces left atrial enlargement in dogs with early preclinical myxomatous mitral valve disease: a blinded randomized controlled study in 36 dogs.
    Li Q; Heaney A; Langenfeld-McCoy N; Boler BV; Laflamme DP
    BMC Vet Res; 2019 Nov; 15(1):425. PubMed ID: 31775756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The predictive value of clinical, radiographic, echocardiographic variables and cardiac biomarkers for assessing risk of the onset of heart failure or cardiac death in dogs with preclinical myxomatous mitral valve disease enrolled in the DELAY study.
    Borgarelli M; Ferasin L; Lamb K; Chiavegato D; Bussadori C; D'Agnolo G; Migliorini F; Poggi M; Santilli RA; Guillot E; Garelli-Paar C; Toschi Corneliani R; Farina F; Zani A; Dirven M; Smets P; Guglielmini C; Oliveira P; Di Marcello M; Porciello F; Crosara S; Ciaramella P; Piantedosi D; Smith S; Vannini S; Dall'Aglio E; Savarino P; Quintavalla C; Patteson M; Silva J; Locatelli C; Baron Toaldo M
    J Vet Cardiol; 2021 Aug; 36():77-88. PubMed ID: 34118562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Mitral INsufficiency Echocardiographic score: A severity classification of myxomatous mitral valve disease in dogs.
    Vezzosi T; Grosso G; Tognetti R; Meucci V; Patata V; Marchesotti F; Domenech O
    J Vet Intern Med; 2021 May; 35(3):1238-1244. PubMed ID: 33951235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of pulmonary vascular resistance estimated by echocardiography in dogs with myxomatous mitral valve disease and pulmonary hypertension.
    Yuchi Y; Suzuki R; Yasumura Y; Saito T; Teshima T; Matsumoto H; Koyama H
    J Vet Intern Med; 2023; 37(3):856-865. PubMed ID: 36994902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of conventional and tissue Doppler echocardiography to predict congestive heart failure in dogs with myxomatous mitral valve disease.
    Kim JH; Park HM
    J Vet Intern Med; 2015 Jan; 29(1):132-40. PubMed ID: 25270196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of focused cardiac ultrasonography training in veterinary students to differentiate stages of subclinical myxomatous mitral valve disease in dogs.
    Huh T; Achilles EJ; Massey LK; Loughran KA; Larouche-Lebel É; Convey V; McKaba VF; Crooks A; Kraus MS; Gelzer AR; Oyama MA
    J Vet Intern Med; 2024; 38(3):1325-1333. PubMed ID: 38532734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.